Future applications of biomarkers in prostate cancer

Panelists discuss how the future of biomarkers in prostate cancer depends on broader clinical adoption, payer coverage, and inclusion in guidelines. Continued data collection and validation will be essential to solidifying their role in standard practice.

Panelists discuss how ongoing educational initiatives and improved access will help clinicians feel more confident incorporating biomarkers. Wider use will be facilitated when providers see consistent real-world outcomes and support from professional societies.

Panelists discuss how biomarkers like IsoPSA have the potential to become routine elements of prostate cancer diagnostics, shaping early detection, patient counseling, and treatment decisions for years to come.